The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

The present invention relates to a process for preparing a mixture of cetylated fatty acids and a system for carrying out said process. Furthermore, the present invention relates to a composition comprising, or alternatively, consisting of said mixture of cetylated fatty acids. Finally, the present invention relates to said composition for use in the treatment and/or prevention of: (i) rheumatoid arthritis of inflammatory and non-inflammatory origin, in particular osteoarthritis; (ii) other inflammatory joint conditions; (iii) psoriasis, lupus, periodontal diseases or cardiovascular or heart diseases; (iv) all post-traumatic osteoarticular pathologies including sports injuries; (v) all degenerative joint pathologies (arthrosis, gonarthrosis, coxarthrosis, etc.), and (vi) inflammatory-traumatic tendon and muscular conditions. Furthermore, it is envisaged that the composition of the present invention be used in the treatment and/or prevention of the above-mentioned pathologies and disorders (i)-(vi) in association with a rehabilitative therapy. The composition comprising said mixture is formulated in a pharmaceutical form for oral use (novel food, supplement or medical device), i.e. in the form of a pill, pastille, capsule, tablet, granules, dispersible powder, syrup, solution or sprayable solution; for topical use, i.e. in the form of a cream, unguent, ointment, gel or spray to be used as such for application on the skin, or else for transdermal use in the form of a patch.